Vita Life Sciences Ltd
ASX:VLS
Vita Life Sciences Ltd
ASX:VLS
Price:
2.51
AUD
-0.4%
Market Closed
Market Cap:
AU$136.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Vita Life Sciences Ltd
ASX:VLS
|
AU |
|
A
|
Amazon.com Inc
XHAM:AMZ
|
US |
|
U
|
UBS Group AG
SWB:0UB
|
CH |
|
Finolex Industries Ltd
NSE:FINPIPE
|
IN |
|
A
|
Accelera Innovations Inc
OTC:ACNV
|
US |
|
N
|
Nissan Motor Co Ltd
XHAM:NISA
|
JP |
|
Atco Ltd
TSX:ACO.X
|
CA |
|
G
|
Golden Metal Resources PLC
LSE:GMET
|
UK |
|
B
|
Black Sea Property AS
OSE:BSP
|
NO |
|
Nevada Exploration Inc
XTSX:NGE
|
CA |
|
Net Talk.com Inc
OTC:NTLK
|
US |
|
Sidetrade SA
PAR:ALBFR
|
FR |
|
Intuitive Investments Group PLC
LSE:IIG
|
UK |
|
C
|
Cyberjaya Education Group Bhd
KLSE:CYBERE
|
MY |
|
E
|
Electrocomponents PLC
LSE:ECM
|
UK |
|
C
|
COFCO Joycome Foods Ltd
HKEX:1610
|
CN |
|
N
|
Netel Holding AB (publ)
STO:NETEL
|
SE |
|
Kaizen Platform Inc
TSE:4170
|
JP |
|
Maritime Resources Corp
XTSX:MAE
|
CA |
|
N
|
Ningbo Heli Technology Co Ltd
SSE:603917
|
CN |
|
Tradelink Electronic Commerce Ltd
HKEX:536
|
HK |
Multiples-Based Value
The
Multiples-Based Value for
Vita Life Sciences Ltd (VLS)
under the Base Case is
hidden
AUD.
Compared with the current market price of 2.51 AUD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VLS Multiples-Based Value
LOCKED
Multiples Across Competitors
VLS Competitors Multiples
Vita Life Sciences Ltd Competitors
Vita Life Sciences Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Vita Life Sciences Ltd
ASX:VLS
|
139.3m AUD | 1.5 | 13.3 | 7.5 | 7.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.5 | 15.9 | 9.9 | 12 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.4 | 16.6 | 7 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
